Study shows birds use social cues to make decisions

eurekalert | May 02, 2019

A new study in The Auk: Ornithological Advances suggests that some birds prioritize social information over visual evidence when making breeding choices. The quality of an environment can be difficult for a bird to assess and, therefore, continuously gathering information is a good way to stay up-to-date with breeding conditions. In this field study, researchers tested how the wild Zebra Finch (Taeniopygia guttata) is attracted to successful nest sites. They presented the Zebra Finch with different visual or acoustic cues in nest boxes, simulating the presence of small or large broods, in order to test how birds assess the quality of a potential breeding site. When discussing the costs and benefits of social information, scientists often argue that socially acquired knowledge is less reliable and more prone to deception. The sounds made by nesting birds, however, are honest indicators of the number of chicks. Predators can use these cues to locate nests. While the calls of chicks serve as signals for the parents and siblings and (inadvertently) also as cues for predators, it is unknown whether chick calls can also function as cues for prospective breeders.

Spotlight

Scully 418 Biotechnology project. Glofish

Spotlight

Scully 418 Biotechnology project. Glofish

Related News

RESEARCH

Immagene and Selvita Announce Integrated Drug Discovery Cooperation

Selvita | February 07, 2022

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is guiding and tapping into Selvita's extensive drug discovery capabilities. Selvita is responsible for a broad range of drug discovery activities including medicinal chemistry supported by computational chemistry, in vitro pharmacology, DMPK and recombinant protein production. Immagene and Selvita are now extending their cooperation. Edyta Jaworska, VP Sales, Drug Discovery Europe and Asia at Selvita Group, comments: "We are truly delighted with the extension of our close collaboration with Immagene. For Selvita's team, it is a perfect opportunity to leverage the full scope of our integrated drug discovery capabilities. This project is exceptionally promising in terms of its therapeutic potential and unique chemistry." Maarten Ligtenberg, PhD, Chief Executive Officer of Immagene "We are confident that our collaboration with Selvita will help us achieve our aim of generating potent first in class small-molecule immune-oncology assets. The rapid turnaround and effective communication allow for the swift development of our programs. We look forward to a longstanding, joint effort to develop innovative therapeutics." To date, Selvita has delivered numerous promising compounds for biology and DMPK screening, and the project has entered the lead optimization phase. The ultimate aim of the cooperation is to provide Immagene with a clinical candidate for unmet immuno-oncology needs. The continued collaboration will help accelerate Immagene's pipeline expansion efforts by leveraging Selvita's fully integrated R&D platform and unique experience in oncology drug discovery and development. About Immagene Immagene B.V. is a private biotech company developing next-generation precision Immuno-Oncology treatments. Founded on world-leading research from the Netherlands Cancer Institute, and drug R&D expertise from industry veterans, we dedicate ourselves to transforming cancer treatment. About Selvita [SLV] Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within drug discovery, regulatory studies, as well as research and development. Selvita Group includes Ardigen – a bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine, and Fidelta, a drug discovery services company specializing in infectious diseases, inflammation, and fibrosis. Selvita Group, established in 2007, operates globally with more than 800 highly qualified employees, of which over 40% hold a PhD degree. The Company's research sites are located in Krakow (HQ) and Poznan, Poland, as well as Zagreb, Croatia (Fidelta). All companies of the Group offer highly synergistic technologies and services.

Read More

MEDTECH

Seegene Develops World's First COVID-19 Diagnostic Variant Test Capable of Identifying Multiple Mutant Variations

Seegene | February 01, 2021

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-19, yet can likewise recognize major genetic variations that appear to have originated from the UK, South Africa just as different districts including Japan and Brazil. Besides, it can pre-screen a suspicious new variant, giving understanding on extra variations, likewise a critical component of Seegene technology. Seegene's new item incorporates in any event ten of its proprietary technologies, including multiplex real-time PCR technique for mTOCE™, which is the forefront technology that solitary Seegene can use. This imaginative technology permits the test to distinguish an objective explicit spot where mutation occurs, empowering exact detection and separation of the Covid just as its transformed versions with a single tube of reagent.

Read More

MEDTECH

Halo Labs Launches the Aura GT™ for Gene Therapy Product Quality

Halo Labs | October 05, 2021

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest product, Aura GT. Aura GT is part of the next generation in Halo Labs' popular family of instruments. Using Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM), Aura GT can distinguish aggregated capsids from contaminants, carrier proteins, and other particles that might adversely harm patients. Unique to Aura GT is the fact that it can also identify DNA leakage in gene therapy products so the mechanism of aggregation can be determined and corrected. Aura GT is going to completely revolutionize gene therapy product development. Gene therapy products are inherently unstable, which is a huge challenge. Up until now, there has been no effective way to correlate capsid aggregation with DNA leakage or empty and full capsids, In one assay, Aura GT can quantify capsid aggregates, distinguish them from protein aggregates, and determine if the aggregation is exacerbated by DNA leaking. - Bernardo Cordovez, Chief Science Officer at Halo Labs. We are very excited to be launching our second instrument this year specifically developed for the cell and gene therapy market, Halo Labs has quickly become a leader in gene therapy analytics because we can answer many questions with very little volume. While other subvisible particle analyzers only do one thing, Aura systems offer a complete multi-assay platform that can be used to fully characterize gene therapy products from early development through lot release. - Rick Gordon, CEO of Halo Labs. About Halo Labs Halo Labs in Burlingame, CA is a venture-backed scientific instrumentation and consumable company that commercializes high throughput biopharmaceutical formulation, stability, and product quality control tools for aggregate and subvisible particle analysis using state-of-the-art custom optics and image processing techniques. Biopharmaceutical companies around the globe depend on Halo Labs for unprecedented insights into their drug products.

Read More